_id
69105e67ccc777a4e85d591c
Ticker
DXCM
Name
DexCom Inc
Exchange
NASDAQ
Address
6340 Sequence Drive, San Diego, CA, United States, 92121
Country
USA
Sector
Healthcare
Industry
Medical Devices
Currency
USD
Website
https://www.dexcom.com
Description
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for the management of diabetes and metabolic health by patients, caregivers, and clinicians. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions; and Stelo, a new over-the-counter glucose biosensor designed for adults with prediabetes and Type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.
Last Close
68.94
Volume
2254792
Current Price
66.96
Change
-2.8720626631853845
Last Updated
2025-11-29T12:28:30.210Z
Image
data:image/webp;base64,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
Ipo Date
2005-04-14T00:00:00.000Z
Market Cap
24890095616
Next Dividend Date
-
Dividend Frequency
-
Dividend Rate
-
Dividend Yield
0
Sentiment
0.45279217391304344
Sentiment Sources
115
Rating
4.5385
Target Price
84.3077
Strong Buy
17
Buy
6
Hold
3
Sell
0
Strong Sell
0
Current Quarter
2025-09-30
Revenue
1209300000
Cost Of Revenue
477900000
Gross Profit
731400000
Operating Expenses
488900000
Operating Income
242500000
Interest Expense
4700000
Pretax Income
352300000
Net Income
283800000
Eps
0.6966126656848306
Dividends Per Share
-
Shares Outstanding
390016272
Income Tax Expense
68500000
EBITDA
415900000
Operating Margin
20.05292317869842
Total Other Income Expense Net
109800000
Cash
1835700000
Short Term Investments
1486400000
Receivables
1109600000
Inventories
604100000
Total Current Assets
5219500000
Property Plant Equipment
1525300000
Total Assets
7500000000
Payables
1932400000
Short Term Debt
1230500000
Long Term Debt
1239900000
Total Liabilities
4773900000
Equity
2726100000
Depreciation
63600000
Change In Working Capital
-22800000
Cash From Operations
659900000
Capital Expenditures
80500000
Cash From Investing
192800000
Cash From Financing
-175000000
Net Change In Cash
676600000
PE
35.2611
PB
10.006787718719048
ROE
10.410476504897105
ROA
3.784
FCF
579400000
Fcf Percent
0.4791201521541388
Piotroski FScore
4
Health Score
63
Deep Value Investing Score
4
Defensive Investing Score
5.5
Dividend Investing Score
3
Economic Moat Investing Score
8.3
Garp Investing Score
6
Growth Investing Score
5
Momentum Investing Score
4
Net Net Investing Score
2.5
Quality Investing Score
8
Value Investing Score
4.5
Quarters > 0 > quarter
2025-09-30
Quarters > 0 > income Statement > revenue
1209300000
Quarters > 0 > income Statement > cost Of Revenue
477900000
Quarters > 0 > income Statement > gross Profit
731400000
Quarters > 0 > income Statement > operating Expenses
488900000
Quarters > 0 > income Statement > operating Income
242500000
Quarters > 0 > income Statement > interest Expense
4700000
Quarters > 0 > income Statement > pretax Income
352300000
Quarters > 0 > income Statement > net Income
283800000
Quarters > 0 > income Statement > eps
0.6966126656848306
Quarters > 0 > income Statement > dividends Per Share
-
Quarters > 0 > income Statement > shares Outstanding
407400000
Quarters > 0 > income Statement > income Tax Expense
68500000
Quarters > 0 > income Statement > EBITDA
415900000
Quarters > 0 > income Statement > operating Margin
20.05292317869842
Quarters > 0 > income Statement > total Other Income Expense Net
109800000
Quarters > 0 > balance Sheet > cash
1835700000
Quarters > 0 > balance Sheet > short Term Investments
1486400000
Quarters > 0 > balance Sheet > receivables
1109600000
Quarters > 0 > balance Sheet > inventories
604100000
Quarters > 0 > balance Sheet > total Current Assets
5219500000
Quarters > 0 > balance Sheet > property Plant Equipment
1525300000
Quarters > 0 > balance Sheet > total Assets
7500000000
Quarters > 0 > balance Sheet > payables
1932400000
Quarters > 0 > balance Sheet > short Term Debt
1230500000
Quarters > 0 > balance Sheet > long Term Debt
1239900000
Quarters > 0 > balance Sheet > total Liabilities
4773900000
Quarters > 0 > balance Sheet > equity
2726100000
Quarters > 0 > cash Flow > net Income
283800000
Quarters > 0 > cash Flow > depreciation
63600000
Quarters > 0 > cash Flow > change In Working Capital
-22800000
Quarters > 0 > cash Flow > cash From Operations
659900000
Quarters > 0 > cash Flow > capital Expenditures
80500000
Quarters > 0 > cash Flow > cash From Investing
192800000
Quarters > 0 > cash Flow > cash From Financing
-175000000
Quarters > 0 > cash Flow > net Change In Cash
676600000
Quarters > 0 > ratios > PE
0.6966126656848306
Quarters > 0 > ratios > PB
10.006787718719048
Quarters > 0 > ratios > ROE
10.410476504897105
Quarters > 0 > ratios > ROA
3.784
Quarters > 0 > ratios > FCF
579400000
Quarters > 0 > ratios > Piotroski FScore
4
Quarters > 0 > ratios > fcf Percent
0.4791201521541388
Quarters > 0 > health Score
63
Quarters > 1 > quarter
2025-06-30
Quarters > 1 > income Statement > revenue
1157100000
Quarters > 1 > income Statement > cost Of Revenue
468300000
Quarters > 1 > income Statement > gross Profit
688800000
Quarters > 1 > income Statement > operating Expenses
476200000
Quarters > 1 > income Statement > operating Income
212600000
Quarters > 1 > income Statement > interest Expense
4700000
Quarters > 1 > income Statement > pretax Income
241100000
Quarters > 1 > income Statement > net Income
179800000
Quarters > 1 > income Statement > eps
0.4404703576678099
Quarters > 1 > income Statement > dividends Per Share
-
Quarters > 1 > income Statement > shares Outstanding
408200000
Quarters > 1 > income Statement > income Tax Expense
61300000
Quarters > 1 > income Statement > EBITDA
308800000
Quarters > 1 > income Statement > operating Margin
18.37352000691384
Quarters > 1 > income Statement > total Other Income Expense Net
28500000
Quarters > 1 > balance Sheet > cash
1159000000
Quarters > 1 > balance Sheet > short Term Investments
1770300000
Quarters > 1 > balance Sheet > receivables
1377000000
Quarters > 1 > balance Sheet > inventories
570700000
Quarters > 1 > balance Sheet > total Current Assets
5030200000
Quarters > 1 > balance Sheet > property Plant Equipment
1513700000
Quarters > 1 > balance Sheet > total Assets
7327000000
Quarters > 1 > balance Sheet > payables
472000000
Quarters > 1 > balance Sheet > short Term Debt
1229500000
Quarters > 1 > balance Sheet > long Term Debt
1238900000
Quarters > 1 > balance Sheet > total Liabilities
4753900000
Quarters > 1 > balance Sheet > equity
2573100000
Quarters > 1 > cash Flow > net Income
179800000
Quarters > 1 > cash Flow > depreciation
63000000
Quarters > 1 > cash Flow > change In Working Capital
22400000
Quarters > 1 > cash Flow > cash From Operations
303000000
Quarters > 1 > cash Flow > capital Expenditures
94100000
Quarters > 1 > cash Flow > cash From Investing
-63600000
Quarters > 1 > cash Flow > cash From Financing
-1700000
Quarters > 1 > cash Flow > net Change In Cash
254200000
Quarters > 1 > ratios > PE
0.4404703576678099
Quarters > 1 > ratios > PB
10.622623294858341
Quarters > 1 > ratios > ROE
6.987680230072675
Quarters > 1 > ratios > ROA
2.453937491469906
Quarters > 1 > ratios > FCF
208900000
Quarters > 1 > ratios > Piotroski FScore
4
Quarters > 1 > ratios > fcf Percent
0.18053755077348543
Quarters > 1 > health Score
57
Quarters > 2 > quarter
2025-03-31
Quarters > 2 > income Statement > revenue
1036000000
Quarters > 2 > income Statement > cost Of Revenue
447000000
Quarters > 2 > income Statement > gross Profit
589000000
Quarters > 2 > income Statement > operating Expenses
455300000
Quarters > 2 > income Statement > operating Income
133700000
Quarters > 2 > income Statement > interest Expense
4700000
Quarters > 2 > income Statement > pretax Income
154300000
Quarters > 2 > income Statement > net Income
105400000
Quarters > 2 > income Statement > eps
0.25865030674846623
Quarters > 2 > income Statement > dividends Per Share
-
Quarters > 2 > income Statement > shares Outstanding
407500000
Quarters > 2 > income Statement > income Tax Expense
48900000
Quarters > 2 > income Statement > EBITDA
219000000
Quarters > 2 > income Statement > operating Margin
12.905405405405403
Quarters > 2 > income Statement > total Other Income Expense Net
20600000
Quarters > 2 > balance Sheet > cash
904900000
Quarters > 2 > balance Sheet > short Term Investments
1796500000
Quarters > 2 > balance Sheet > receivables
1169900000
Quarters > 2 > balance Sheet > inventories
538200000
Quarters > 2 > balance Sheet > total Current Assets
4553800000
Quarters > 2 > balance Sheet > property Plant Equipment
1423800000
Quarters > 2 > balance Sheet > total Assets
6751700000
Quarters > 2 > balance Sheet > payables
432000000
Quarters > 2 > balance Sheet > short Term Debt
1227900000
Quarters > 2 > balance Sheet > long Term Debt
1238000000
Quarters > 2 > balance Sheet > total Liabilities
4485100000
Quarters > 2 > balance Sheet > equity
2266600000
Quarters > 2 > cash Flow > net Income
105400000
Quarters > 2 > cash Flow > depreciation
60000000
Quarters > 2 > cash Flow > change In Working Capital
400000
Quarters > 2 > cash Flow > cash From Operations
183800000
Quarters > 2 > cash Flow > capital Expenditures
87000000
Quarters > 2 > cash Flow > cash From Investing
100200000
Quarters > 2 > cash Flow > cash From Financing
12500000
Quarters > 2 > cash Flow > net Change In Cash
298800000
Quarters > 2 > ratios > PE
0.25865030674846623
Quarters > 2 > ratios > PB
12.038383481867111
Quarters > 2 > ratios > ROE
4.650136768728492
Quarters > 2 > ratios > ROA
1.5610883184975637
Quarters > 2 > ratios > FCF
96800000
Quarters > 2 > ratios > Piotroski FScore
4
Quarters > 2 > ratios > fcf Percent
0.09343629343629344
Quarters > 2 > health Score
46
Quarters > 3 > quarter
2024-12-31
Quarters > 3 > income Statement > revenue
1113500000
Quarters > 3 > income Statement > cost Of Revenue
457700000
Quarters > 3 > income Statement > gross Profit
655800000
Quarters > 3 > income Statement > operating Expenses
466900000
Quarters > 3 > income Statement > operating Income
188900000
Quarters > 3 > income Statement > interest Expense
4900000
Quarters > 3 > income Statement > pretax Income
211300000
Quarters > 3 > income Statement > net Income
151700000
Quarters > 3 > income Statement > eps
0.3730022129333661
Quarters > 3 > income Statement > dividends Per Share
-
Quarters > 3 > income Statement > shares Outstanding
406700000
Quarters > 3 > income Statement > income Tax Expense
59600000
Quarters > 3 > income Statement > EBITDA
274000000
Quarters > 3 > income Statement > operating Margin
16.964526268522675
Quarters > 3 > income Statement > total Other Income Expense Net
22400000
Quarters > 3 > balance Sheet > cash
606100000
Quarters > 3 > balance Sheet > short Term Investments
1973300000
Quarters > 3 > balance Sheet > receivables
1033600000
Quarters > 3 > balance Sheet > inventories
542600000
Quarters > 3 > balance Sheet > total Current Assets
4301400000
Quarters > 3 > balance Sheet > property Plant Equipment
1402700000
Quarters > 3 > balance Sheet > total Assets
6484500000
Quarters > 3 > balance Sheet > payables
345300000
Quarters > 3 > balance Sheet > short Term Debt
1226900000
Quarters > 3 > balance Sheet > long Term Debt
1237000000
Quarters > 3 > balance Sheet > total Liabilities
4381900000
Quarters > 3 > balance Sheet > equity
2102600000
Quarters > 3 > cash Flow > net Income
151700000
Quarters > 3 > cash Flow > depreciation
57800000
Quarters > 3 > cash Flow > change In Working Capital
6400000
Quarters > 3 > cash Flow > cash From Operations
301400000
Quarters > 3 > cash Flow > capital Expenditures
124600000
Quarters > 3 > cash Flow > cash From Investing
-303700000
Quarters > 3 > cash Flow > cash From Financing
-1600000
Quarters > 3 > cash Flow > net Change In Cash
-15100000
Quarters > 3 > ratios > PE
0.3730022129333661
Quarters > 3 > ratios > PB
12.951884333682106
Quarters > 3 > ratios > ROE
7.214876819176258
Quarters > 3 > ratios > ROA
2.3394247821728738
Quarters > 3 > ratios > FCF
176800000
Quarters > 3 > ratios > Piotroski FScore
4
Quarters > 3 > ratios > fcf Percent
0.15877862595419848
Quarters > 3 > health Score
51
Valuation > metrics > PE
35.2611
Valuation > metrics > PB
10.006787718719048
Valuation > final Score
7.686680000000003
Valuation > verdict
137.3% Overvalued
Profitability > metrics > ROE
10.410476504897105
Profitability > metrics > ROA
5.437302423603793
Profitability > metrics > Net Margin
0.23468122054080873
Profitability > final Score
67
Profitability > verdict
Adequate
Risk > metrics > Debt Equity
1.7511830086937383
Risk > metrics > Interest Coverage
51.59574468085106
Risk > final Score
70
Risk > verdict
Low
Liquidity > metrics > Current Ratio
1.6502260583641595
Liquidity > metrics > Quick Ratio
1.459230453065225
Liquidity > final Score
91
Liquidity > verdict
Great
Prev Valuations > 0
40
Prev Valuations > 1
40
Prev Valuations > 2
40
Prev Profitabilities > 0
48
Prev Profitabilities > 1
32
Prev Profitabilities > 2
45
Prev Risks > 0
70
Prev Risks > 1
70
Prev Risks > 2
58
Prev Liquidities > 0
100
Prev Liquidities > 1
100
Prev Liquidities > 2
100
Updated At
2025-12-14T00:24:33.472Z
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for the management of diabetes and metabolic health by patients, caregivers, and clinicians. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions; and Stelo, a new over-the-counter glucose biosensor designed for adults with prediabetes and Type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.
Stock Price
$ 0.00
0% decrease compared to yesterday.
Dividend
Frequency:
Rate:
N/ANext Payout:
N/ADXCM Deadline: DXCM Investors with Losses in Excess of $100K Have Opportunity to Lead DexCom, Inc. Securities Fraud Lawsuit marketscreener.com
Read more →Showing 2 of 10
(Last Updated 2025-09-30)
Rating:
STRONG BUY
Target Price:
$84.3077
Analyst Picks
Strong Buy
17
Buy
6
Hold
3
Sell
0
Strong Sell
0
Sentiment:
Bullish
(Last Updated 2025-09-30)
Health Score
Price to Earnings Ratio (P/E)
-
Low
Low ≥ 50
High ≤ 10
Price to Book Ratio (P/B)
-
Very High
Low ≤ 1
High ≥ 3
Return on Equity (ROE)
-
Low
Low ≤ 5%
High ≥ 25%
Return on Assets (ROA)
-
Low
Low ≤ 2%
High ≥ 10%
Free Cash Flow - Revenue % (FCF)
-
Very High
Low ≤ 5%
High ≥ 15%
Debt to Equity
-
Very Low
Low ≥ 1
High ≤ 0.3
* Institutions hold a combined 80.75% of the total shares of DexCom Inc
1.
Vanguard Group Inc(12.3223%)
since
2025/06/30
2.
BlackRock Inc(9.9532%)
since
2025/06/30
3.
State Street Corp(4.2988%)
since
2025/06/30
4.
Baillie Gifford & Co Limited.(4.2598%)
since
2025/06/30
5.
Vanguard Total Stock Mkt Idx Inv(3.1427%)
since
2025/07/31
6.
Jennison Associates LLC(2.937%)
since
2025/06/30
7.
Geode Capital Management, LLC(2.7454%)
since
2025/06/30
8.
Sands Capital Management, LLC(2.5367%)
since
2025/06/30
9.
Vanguard 500 Index Investor(2.4745%)
since
2025/07/31
10.
UBS Asset Mgmt Americas Inc(2.3283%)
since
2025/06/30
11.
Vanguard Mid Cap Index Institutional(2.2305%)
since
2025/07/31
12.
Invesco QQQ Trust(2.0609%)
since
2025/08/29
13.
Nuveen, LLC(1.9301%)
since
2025/06/30
14.
Massachusetts Financial Services Company(1.6845%)
since
2025/06/30
15.
JPMorgan Chase & Co(1.5694%)
since
2025/06/30
16.
Morgan Stanley - Brokerage Accounts(1.4287%)
since
2025/06/30
17.
Capital Research Global Investors(1.3787%)
since
2025/06/30
18.
NORGES BANK(1.3242%)
since
2025/06/30
19.
Fidelity 500 Index(1.2674%)
since
2025/07/31
20.
Amvescap Plc.(1.2652%)
since
2025/06/30
21.
SPDR® S&P 500® ETF(1.2105%)
since
2025/08/31
22.
iShares Core S&P 500 ETF(1.203%)
since
2025/08/31
23.
Vanguard Growth Index Investor(1.1633%)
since
2025/07/31
24.
Sands Capital Global Growth Equity(1.1309%)
since
2025/06/30
25.
Amundi(1.1127%)
since
2025/06/30
26.
Groupama Asset Management(1.0242%)
since
2025/06/30
27.
American Century Companies Inc(0.9918%)
since
2025/06/30
28.
Bank of New York Mellon Corp(0.9854%)
since
2025/06/30
29.
Northern Trust Corp(0.978%)
since
2025/06/30
30.
CREF Growth R3(0.899%)
since
2025/07/31
31.
Vanguard Mid-Cap Growth ETF(0.8351%)
since
2025/07/31
32.
BlackRock Mid-Cap Growth Equity Instl(0.7722%)
since
2025/07/31
33.
Sands Capital Select Growth TE Inst EQ(0.7702%)
since
2025/06/30
34.
MFS Mid Cap Growth Equity(0.699%)
since
2025/06/30
35.
The Health Care Select Sector SPDR® ETF(0.6827%)
since
2025/08/31
36.
Harbor Capital Appreciation Instl(0.6813%)
since
2025/06/30
37.
MFS Mid Cap Growth A(0.6808%)
since
2025/07/31
38.
iShares Russell Mid-Cap Growth ETF(0.6567%)
since
2025/08/31
39.
Vanguard Institutional Index I(0.6047%)
since
2025/07/31
40.
State St S&P 500® Indx SL Cl III(0.5337%)
since
2025/08/31
* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.
No earnings data available.
(Last Updated 2025-09-30)
(Last Updated 2025-09-30)
Revenue
$ 0
Cost Of Revenue
$ 0
Gross Profit
$ 0
Operating Expenses
$ 0
Operating Income
$ 0
Interest Expense
$ 0
Pretax Income
$ 0
Net Income
$ 0
Income Tax Expense
$ 0
EBITDA
$ 0
Total Other Income Expense Net
$ 0
Earnings Per Share
0
Dividends Per Share
0
Shares Outstanding
0
Operating Margin
0%
(Last Updated 2025-09-30)
Cash
$ 0
Short Term Investments
$ 0
Receivables
$ 0
Inventories
$ 0
Total Current Assets
$ 0
Property Plant Equipment
$ 0
Total Assets
$ 0
Payables
$ 0
Short Term Debt
$ 0
Long Term Debt
$ 0
Total Liabilities
$ 0
Equity
$ 0
(Last Updated 2025-09-30)
Net Income
$ 0
Depreciation
$ 0
Change In Working Capital
$ 0
Cash From Operations
$ 0
Capital Expenditures
$ 0
Cash From Investing
$ 0
Cash From Financing
$ 0
Net Change In Cash
$ 0
Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.